Shots:
- Roche reported positive topline results from the P-II (CT388-103) study evaluating CT-388, an investigational dual GLP-1/GIP receptor agonist, for the treatment of obesity
- Once-weekly CT-388 (SC) achieved a statistically significant PBO-adjusted weight loss of 22.5% (p<0.001; efficacy estimand) at 48 wks. at the highest dose (24 mg), with no weight-loss plateau observed; 54% of pts achieved obesity resolution (BMI <30 kg/m²) vs 13% with PBO
- CT-388 showed a safety and tolerability profile consistent with the incretin class; Roche plans to advance CT-388 into P-III study (Enith1 & Enith2) starting this quarter (Q1’26)
Ref: Roche | Image: Roche | Press Release
Related News: Roche Receives the Health Canada Approval for Gazyva to Treat Active Lupus Nephritis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
